Mircera (Methoxy polyethylene glycol-epoetin beta) is designed to stimulate red blood cell production and is indicated for patients with CKD-related anemia. Unlike conventional ESAs, Mircera has a prolonged half-life, allowing for less frequent dosing.
Key Features:
Active Ingredient: Methoxy polyethylene glycol-epoetin beta
Strength: 50 mcg / 0.3 mL
Form: Injectable solution (pre-filled syringe)
Manufacturer: Roche
Indications:
Mircera is prescribed for:
- Anemia associated with chronic kidney disease (CKD) in adults
- Maintenance of hemoglobin levels in dialysis and non-dialysis patients
Administration and Dosage:
Administered via subcutaneous or intravenous injection. The dosing frequency is typically once every two to four weeks, depending on the patient’s condition and response to treatment.
Storage Instructions:
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and keep in the original packaging.
Precautions:
Monitor hemoglobin levels to avoid excessive increases that may lead to cardiovascular complications. Not recommended for patients with uncontrolled hypertension.
Note: This is a prescription-only medication and should be used under the supervision of a healthcare professional.
Reviews
There are no reviews yet.